We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Molecule Imaging Reveals How Telomerase Finds and Binds to the Telomere

By LabMedica International staff writers
Posted on 31 Aug 2016
Genomics researchers have combined the CRISPR/Cas9 gene editing technique with advanced single-molecule imaging technology to demonstrate how the enzyme telomerase finds and attaches to the telomere, the region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes.

Telomerase maintains genome integrity by adding repetitive DNA sequences to the chromosome ends in actively dividing cells, including 90% of all cancer cells. More...
Recruitment of human telomerase to telomeres occurs during S-phase of the cell cycle, but the molecular mechanism of the process is only partially understood.

To examine this mechanism, investigators at the University of Colorado Cancer Center (Denver) used the CRISPR/Cas9 gene editing technique to insert the gene for a fluorescent protein marker into the telomerase gene, which resulted in telomerase proteins that could be observed under a fluorescent microscope. The marked telomerase molecules were tracked with a single-molecule imaging system in the nuclei of living human cells.

The investigators reported in the August 11, 2016, online edition of the journal Cell that telomerase used three-dimensional diffusion to search for telomeres, probing each telomere thousands of times each S-phase but only rarely forming a stable association. Both the transient and stable association events depended on the direct interaction of the telomerase protein TERT (Telomerase reverse transcriptase) with the telomeric protein TPP1. When telomerase found and attached to a telomere, it added a repeating DNA sequence to the repeating DNA sequences that were already in place, lengthening the telomere and adding to the chromosome's protective ends.

"Right now we do not have a great telomerase inhibitor. We do not know at which step our first generation of these drugs is interfering so we do not know how to optimize these drug candidates for anti-cancer effect," said senior author Dr. Thomas Cech, Nobel Prize winning professor of chemistry and biochemistry at the University of Colorado. "Does a drug prevent the assembly of telomerase? Does it keep telomerase from moving near telomeres? Does it prevent telomerase from finding a telomere end? Knowing where a drug blocks the ability of telomerase to lengthen telomeres could have broad applicability for diverse cancers."

Related Links:
University of Colorado Cancer Center



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.